Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Future Prospects | Delve into Vor's assets, including intellectual property and manufacturing capabilities, that could prove valuable in potential strategic transactions |
Market Valuation Gap | Explore the intriguing disparity between Vor's stock price and its estimated pro forma cash value, presenting potential opportunities for investors |
Financial Health | With $92 million in cash but a weak financial health score, Vor faces a critical juncture as it navigates its strategic shift and preserves shareholder value |
Strategic Pivot | Vor Biopharma halts all development programs and explores strategic alternatives amid challenging market conditions and disappointing clinical results |
Metrics to compare | VOR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVORPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.2x | −2.9x | −0.5x | |
PEG Ratio | 0.01 | −0.09 | 0.00 | |
Price / Book | −5.1x | 3.7x | 2.6x | |
Price / LTM Sales | - | 18.4x | 3.2x | |
Upside (Analyst Target) | 152.0% | 142.8% | 47.6% | |
Fair Value Upside | Unlock | 4.3% | 6.1% | Unlock |